PMID- 29512070
OWN - NLM
STAT- MEDLINE
DCOM- 20190206
LR  - 20190215
IS  - 1940-6029 (Electronic)
IS  - 1064-3745 (Linking)
VI  - 1750
DP  - 2018
TI  - Blood-Based Biomarker Screening with Agnostic Biological Definitions for an 
      Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases.
PG  - 139-155
LID - 10.1007/978-1-4939-7704-8_9 [doi]
AB  - The discovery, development, and validation of novel candidate biomarkers in 
      Alzheimer's disease (AD) and other neurodegenerative diseases (NDs) are 
      increasingly gaining momentum. As a result, evolving diagnostic research criteria 
      of NDs are beginning to integrate biofluid and neuroimaging indicators of 
      pathophysiological mechanisms. More than 10% of people aged over 65 suffer from 
      NDs. There is an urgent need for a refined two-stage diagnostic model to first 
      initiate an early, sensitive, and noninvasive process in primary care settings. 
      Individuals that meet detection criteria will then be channeled to more specific, 
      costly (positron-emission tomography), and invasive (cerebrospinal fluid) 
      assessment methods for confirmatory biological characterization and diagnosis.A 
      reliable and sensitive blood test for AD and other NDs is not yet established; 
      however, it would provide the golden screening gate for an efficient primary care 
      management. A limitation to the development of a large-scale blood-screening 
      biomarker-based test is the traditional application of clinically descriptive 
      criteria for the categorization of single late-stage ND constructs. These are 
      genetically and biologically heterogeneous, reflected in multiple 
      pathophysiological mechanisms and subsequent pathologies throughout a dimensional 
      continuum. Evidence suggests that a shared, "open-source" integrated multilevel 
      categorization of NDs that clusters individuals based on descriptive clinical 
      phenotypes and pathophysiological biomarker signatures will provide the next 
      incremental step toward an improved diagnostic process of NDs. This intermediate 
      objective toward unbiased biomarker-guided early detection of individuals at risk 
      for NDs is currently carried out by the international pilot Alzheimer Precision 
      Medicine Initiative Cohort Program (APMI-CP).
FAU - Baldacci, Filippo
AU  - Baldacci F
AD  - AXA Research Fund & UPMC Chair, F-75013, Paris, France.
AD  - Sorbonne Universite, AP-HP, GRC n degrees  21, Alzheimer Precision Medicine (APM), 
      Hopital de la Pitie-Salpetriere, Boulevard de l'hopital, F-75013, Paris, France.
AD  - Institut du Cerveau et de la Moelle Epiniere (ICM), INSERM U 1127, CNRS UMR 7225, 
      Boulevard de l'hopital, F-75013, Paris, France.
AD  - Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de 
      Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Boulevard de l'hopital, 
      F-75013, Paris, France.
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
      Italy.
FAU - Lista, Simone
AU  - Lista S
AD  - AXA Research Fund & UPMC Chair, F-75013, Paris, France. slista@libero.it.
AD  - Sorbonne Universite, AP-HP, GRC n degrees  21, Alzheimer Precision Medicine (APM), 
      Hopital de la Pitie-Salpetriere, Boulevard de l'hopital, F-75013, Paris, France. 
      slista@libero.it.
AD  - Institut du Cerveau et de la Moelle Epiniere (ICM), INSERM U 1127, CNRS UMR 7225, 
      Boulevard de l'hopital, F-75013, Paris, France. slista@libero.it.
AD  - Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de 
      Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Boulevard de l'hopital, 
      F-75013, Paris, France. slista@libero.it.
FAU - O'Bryant, Sid E
AU  - O'Bryant SE
AD  - Institute for Healthy Aging, University of North Texas Health Science Center, 
      Fort Worth, TX, USA.
FAU - Ceravolo, Roberto
AU  - Ceravolo R
AD  - Department of Clinical and Experimental Medicine, University of Pisa, Pisa, 
      Italy.
FAU - Toschi, Nicola
AU  - Toschi N
AD  - Department of Biomedicine and Prevention, University of Rome "Tor Vergata", Rome, 
      Italy.
AD  - Department of Radiology"Athinoula A. Martinos", Center for Biomedical Imaging, 
      Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Hampel, Harald
AU  - Hampel H
AD  - AXA Research Fund & UPMC Chair, F-75013, Paris, France.
AD  - Sorbonne Universite, AP-HP, GRC n degrees  21, Alzheimer Precision Medicine (APM), 
      Hopital de la Pitie-Salpetriere, Boulevard de l'hopital, F-75013, Paris, France.
AD  - Institut du Cerveau et de la Moelle Epiniere (ICM), INSERM U 1127, CNRS UMR 7225, 
      Boulevard de l'hopital, F-75013, Paris, France.
AD  - Institut de la Memoire et de la Maladie d'Alzheimer (IM2A), Departement de 
      Neurologie, Hopital de la Pitie-Salpetriere, AP-HP, Boulevard de l'hopital, 
      F-75013, Paris, France.
CN  - Alzheimer Precision Medicine Initiative (APMI)
LA  - eng
GR  - R01 AG051848/AG/NIA NIH HHS/United States
GR  - R56 AG054073/AG/NIA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Methods Mol Biol
JT  - Methods in molecular biology (Clifton, N.J.)
JID - 9214969
RN  - 0 (Biomarkers)
SB  - IM
MH  - Biomarkers/*blood
MH  - Early Diagnosis
MH  - Humans
MH  - Mass Screening
MH  - Neurodegenerative Diseases/*blood/*diagnosis
MH  - Precision Medicine/*methods
OTO - NOTNLM
OT  - Alzheimer precision medicine initiative
OT  - Alzheimer's disease
OT  - Biomarkers
OT  - Blood
OT  - Neurodegenerative diseases
OT  - Pathophysiology
OT  - Precision medicine
OT  - Screening
OT  - Systems biology
OT  - Systems neurophysiology
EDAT- 2018/03/08 06:00
MHDA- 2019/02/07 06:00
CRDT- 2018/03/08 06:00
PHST- 2018/03/08 06:00 [entrez]
PHST- 2018/03/08 06:00 [pubmed]
PHST- 2019/02/07 06:00 [medline]
AID - 10.1007/978-1-4939-7704-8_9 [doi]
PST - ppublish
SO  - Methods Mol Biol. 2018;1750:139-155. doi: 10.1007/978-1-4939-7704-8_9.